SCOTUS allows early notice from biosimilar applicants
12-06-2017
Fed Circuit erred in Sandoz v Amgen, says solicitor general
28-02-2017
Brandon Bourdages / Shutterstock.com
The US Supreme Court has agreed to hear the biosimilars dispute between Amgen and Sandoz.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
SCOTUS, Sandoz, Amgen, biosimilar, Neupogen, Zarxio, BPCIA
